Congratulations to Life Biosciences, a valued partner of the LBA, for being named a 2024 INNOFIRE Award honoree by BostInno! Life Biosciences is at the forefront of developing cellular rejuvenation therapies aimed at reversing and preventing age-related diseases. They recognize that aging is the primary modifiable risk factor for most chronic diseases, driven by specific biological mechanisms that can be therapeutically targeted. Their work focuses on two key platforms: Partial Epigenetic Reprogramming Platform Life Biosciences is developing therapies that induce the expression of three Yamanaka factors—OCT4, SOX2, and KLF4 (OSK)—to reprogram the epigenome. Their gene therapy candidates have shown promising safety and efficacy in preclinical studies, including mouse models for nerve damage and glaucoma, as well as a non-human primate model for non-arteritic anterior ischemic optic neuropathy (NAION). Chaperone-Mediated Autophagy Platform The company is also advancing small molecule activators of chaperone-mediated autophagy, which reduce the buildup of aggregated proteins. These molecules have demonstrated safety and efficacy in preclinical models of neurodegenerative and retinal diseases. Life Biosciences' innovative approach continues to push the boundaries of therapeutic development, addressing the fundamental causes of aging. This recognition is truly well deserved.
We are excited to share that Life Biosciences has been named a 2024 #INNOFIRE Award honoree by BostInno! This competitive award celebrates our efforts in advancing #CellularRejuvenation therapies to reverse and prevent diseases of aging, positioning us among the leading innovators in Boston’s thriving biotech scene. Thank you to our incredible team and supporters for helping us reach this milestone. Learn more: https://bit.ly/4f4MR2u